Ask AI
ProCE Banner Activity

TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Strategies, and Practical Toxicity Management

Slideset

TROP2-directed antibody–drug conjugates (ADCs) are expanding treatment options for patients with advanced non-small-cell lung cancer (NSCLC), bringing new considerations for treatment selection, sequencing, and toxicity management. In this downloadable teaching resource, you will find expert-led information on the current and evolving role of TROP2-directed ADCs in NSCLC. Topics covered include treatment of EGFR-mutated disease, emerging clinical trial evidence for ADC combinations, biomarker-driven approaches, and multidisciplinary strategies to prevent, recognize, and manage key adverse events.

Released: November 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for medical oncologists, pulmonologists, and other healthcare professionals involved in the care of patients with advanced/metastatic NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the current and evolving role of TROP2-directed ADCs in advanced/metastatic NSCLC, including current evidence-based use of Dato-DXd and emerging investigational strategies across frontline, biomarker-enriched, and combination settings

  • Apply established biomarkers and patient-specific clinical factors to guide selection, sequencing, and clinical trial referral for TROP2-directed ADCs and ADC-based strategies in advanced/metastatic NSCLC

  • Appraise emerging global clinical trial evidence for TROP2-directed ADCs, including Dato-DXd, sac-TMT/MK-2870, ADC–immunotherapy combinations, ADC–EGFR TKI combinations, and biomarker-driven approaches

  • Implement multidisciplinary strategies to prevent, monitor, and manage TROP2 ADC–associated adverse events, including stomatitis/oral mucositis, ocular toxicity, nausea, myelosuppression, and ILD/pneumonitis